Mpox: NCDC confirms 40 out of 830 suspected cases

• Nigeria To Receive Doses Of Mpox Vaccine From U.S. Govt
• Nation Not At High Risk Of Mpox Spread – WHO

The Nigeria Centre for Disease Control and Prevention (NCDC) has recorded 40 confirmed cases of Mpox out of the 830 suspected cases in the country.But the World Health Organisation (WHO) has said that Nigeria is not at high risk but rather moderate risk of the spread of Mpox.

It, however, stressed the need for the country to remain vigilant considering that cases were being reported as far as Europe and Asia. Fortunately, Nigeria will receive doses of Mpox vaccine through donation from the U.S. government.  

Speaking at the Joint NCDC/WHO National Mpox Briefing with stakeholders and partners in Abuja on Friday, Director General of the NCDC, Dr. Jide Idris, said the NCDC has met with the state governments and the state commissioners of health, basically to intimate them on the need to establish their own emergency preparedness and response teams, capabilities and action plans with the support of the centre.

He said: “We discussed what they are going to do in conjunction with their various local government areas; that is, in terms of coordination and incident management system. The essence is that the problems are at the sub-national level.  We need to see how we can all collaborate to reduce the incidence of this disease in Nigeria, Africa and globally.”

Idris noted that after the Mpox was declared public health emergency of international concern, Nigeria activated an Emergency Operations Centre (EOC), adding that it has established an incident management system and incident action plan on what should be done including costs for each using the different pillars.  

He said: “Looking at the number of cases we have in the country, which is about 40, quite a number of them are in about 12 or 13 states. A number of the cases are in the South-South, South-East, some in Lagos, Ogun and up North. Looking at the distribution, our plans now are to target those states so that we can reduce the number of cases through active surveillance to detect more cases.

“We have to beef up our laboratory services. All the cases we have seen so far were confirmed using genomic sequencing in two labs, National Research Lab in Abuja and in Lagos. But because of the spread, we need to increase the number of laboratories we are going to use to test. So, we are including LUTH and the African Centre for Genomics (ACG). 

“More importantly, we need to increase all the laboratory capabilities, especially in the South-South, South-East area. We also know that in our network, quite a number of laboratories have the capacity to do PCR, but they may not be able to test for Mpox. So, we need to beef up those capabilities, either by training or by supplying them with necessary reagents and consumables. We have identified a number of laboratories that are looking into that,” he added. 

The NCDC boss stated that the centre was intensifying efforts to enlighten the public on what Mpox is, how it presents and what people can do to reduce or prevent the spread.

“The spread is based by contact with infected animals or infected humans. So, once you can reduce, stop that contact, the transmission can’t easily be done. Although some cases, especially those that were caused by clade 1B, have sexual transmission; also some airborne. And that’s the essence of this public enlightenment, public awareness, which we need to intensify.”

On the challenges so far, Idris said: “There are some challenges we have; we were addressing in terms of data collection, for instance. We know that there are three states we have not reported anything; some states may not report these cases because of stigma issues or we consider it as not visible to them. Like we did for cholera, we are sending people out. We hope to get more cases. The objective is to reduce the number of cases but we need to intensify active search. All the cases we have here are the clade 2B type, the less serious type, but we also have to be on the alert for clade 1B.”

Also speaking, Country Representative of the WHO, Dr. Walter Mulombo, said the organisation would continue to work with the Federal Government to strengthen public health measures that are needed to control the outbreak. 

Mulombo noted that the there was a huge demand for Mpox vaccine, which was in short supply, adding that the capacity of the current manufacturer could not meet the global demand unless some kind of intervention surfaces.He said: “Nigeria will be receiving a number of doses of vaccine through donation from the U.S. government. The needs globally are huge but the vaccine in is in short supply.”

Mulombo stressed the need for Nigeria to optimise and increase the number of laboratories to enhance case detection.

“We showed that the epicentre for this new emergency of international concern is in Central Africa and neighbouring countries. It’s triggered by the appearance of the new gladiator. It’s an opportunity. So, it’s ringing the bell on the need to remain vigilant and continue to monitor microbes in nature causing the disease. So, we were able to show the picture in Africa, also outside Africa, where we have observed already cases in Europe and now in Asia. And of course, Nigeria is not high risk; it’s moderate risk but we need to continue to remain vigilant because we have cases reported as far as Europe or Asia and Nigeria is not safe until all countries are safe,” he added.